FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113805975> ?p ?o ?g. }

• W2113805975 endingPage "340" @default.
• W2113805975 startingPage "330" @default.
• W2113805975 abstract "Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitrone compound OKN-007, a disulfonyl derivative of α-phenyl-tert-butyl nitrone. MRI was used to assess tumor volumes in F98 and U87 gliomas, and bioluminescence imaging was used to measure tumor volumes in F98 gliomas encoded with the luciferase gene (F98luc). Immunohistochemistry was used to assess angiogenesis (vascular endothelial growth factor [VEGF] and microvessel density [MVD]), cell differentiation (carbonic anhydrase IX [CA-IX]), hypoxia (hypoxia-inducible factor-1α [HIF-1α]), cell proliferation (glucose transporter 1 [Glut-1] and MIB-1), proliferation index, and apoptosis (cleaved caspase 3) markers in F98 gliomas. VEGF, CA-IX, Glut-1, HIF-1α, and cleaved caspase 3 were assessed in U87 gliomas. Animal survival was found to be significantly increased (P < .001 for F98, P < .01 for U87) in the group that received OKN-007 treatment compared with the untreated groups. After MRI detection of F98 gliomas, OKN-007, administered orally, was found to decrease tumor growth (P < .05). U87 glioma volumes were found to significantly decrease (P < .05) after OKN-007 treatment, compared with untreated animals. OKN-007 administration resulted in significant decreases in tumor hypoxia (HIF-1α [P < .05] in both F98 and U87), angiogenesis (MVD [P < .05], but not VEGF, in F98 or U87), and cell proliferation (Glut-1 [P < .05 in F98, P < .01 in U87] and MIB-1 [P < .01] in F98) and caused a significant increase in apoptosis (cleaved caspase 3 [P < .001 in F98, P < .05 in U87]), compared with untreated animals. OKN-007 may be considered as a promising therapeutic addition or alternative for the treatment of aggressive human gliomas." @default.
• W2113805975 created "2016-06-24" @default.
• W2113805975 creator A5003655962 @default.
• W2113805975 creator A5018148562 @default.
• W2113805975 creator A5021509527 @default.
• W2113805975 creator A5035326340 @default.
• W2113805975 creator A5037688456 @default.
• W2113805975 creator A5046466118 @default.
• W2113805975 creator A5048536619 @default.
• W2113805975 creator A5053353923 @default.
• W2113805975 creator A5054614086 @default.
• W2113805975 creator A5057897360 @default.
• W2113805975 creator A5073331119 @default.
• W2113805975 creator A5076585065 @default.
• W2113805975 creator A5080895084 @default.
• W2113805975 creator A5082065708 @default.
• W2113805975 date "2013-01-17" @default.
• W2113805975 modified "2023-10-14" @default.
• W2113805975 title "Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007" @default.
• W2113805975 cites W1518975508 @default.
• W2113805975 cites W191454705 @default.
• W2113805975 cites W1985156459 @default.
• W2113805975 cites W1986718067 @default.
• W2113805975 cites W1997227020 @default.
• W2113805975 cites W1997364324 @default.
• W2113805975 cites W1997884315 @default.
• W2113805975 cites W2016038944 @default.
• W2113805975 cites W2019615205 @default.
• W2113805975 cites W2020217107 @default.
• W2113805975 cites W2031675718 @default.
• W2113805975 cites W2031806733 @default.
• W2113805975 cites W2032930328 @default.
• W2113805975 cites W2035182290 @default.
• W2113805975 cites W2046212337 @default.
• W2113805975 cites W2055946117 @default.
• W2113805975 cites W2065983942 @default.
• W2113805975 cites W2102488910 @default.
• W2113805975 cites W2115104536 @default.
• W2113805975 cites W2120710695 @default.
• W2113805975 cites W2134590544 @default.
• W2113805975 cites W2145281954 @default.
• W2113805975 cites W2145299723 @default.
• W2113805975 cites W2154079316 @default.
• W2113805975 cites W2165464170 @default.
• W2113805975 cites W2169869816 @default.
• W2113805975 doi "https://doi.org/10.1093/neuonc/nos337" @default.
• W2113805975 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3578492" @default.
• W2113805975 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23328810" @default.
• W2113805975 hasPublicationYear "2013" @default.
• W2113805975 type Work @default.
• W2113805975 sameAs 2113805975 @default.
• W2113805975 citedByCount "35" @default.
• W2113805975 countsByYear W21138059752014 @default.
• W2113805975 countsByYear W21138059752015 @default.
• W2113805975 countsByYear W21138059752016 @default.
• W2113805975 countsByYear W21138059752017 @default.
• W2113805975 countsByYear W21138059752018 @default.
• W2113805975 countsByYear W21138059752019 @default.
• W2113805975 countsByYear W21138059752020 @default.
• W2113805975 countsByYear W21138059752021 @default.
• W2113805975 countsByYear W21138059752022 @default.
• W2113805975 countsByYear W21138059752023 @default.
• W2113805975 crossrefType "journal-article" @default.
• W2113805975 hasAuthorship W2113805975A5003655962 @default.
• W2113805975 hasAuthorship W2113805975A5018148562 @default.
• W2113805975 hasAuthorship W2113805975A5021509527 @default.
• W2113805975 hasAuthorship W2113805975A5035326340 @default.
• W2113805975 hasAuthorship W2113805975A5037688456 @default.
• W2113805975 hasAuthorship W2113805975A5046466118 @default.
• W2113805975 hasAuthorship W2113805975A5048536619 @default.
• W2113805975 hasAuthorship W2113805975A5053353923 @default.
• W2113805975 hasAuthorship W2113805975A5054614086 @default.
• W2113805975 hasAuthorship W2113805975A5057897360 @default.
• W2113805975 hasAuthorship W2113805975A5073331119 @default.
• W2113805975 hasAuthorship W2113805975A5076585065 @default.
• W2113805975 hasAuthorship W2113805975A5080895084 @default.
• W2113805975 hasAuthorship W2113805975A5082065708 @default.
• W2113805975 hasBestOaLocation W21138059751 @default.
• W2113805975 hasConcept C128473837 @default.
• W2113805975 hasConcept C142724271 @default.
• W2113805975 hasConcept C167734588 @default.
• W2113805975 hasConcept C185592680 @default.
• W2113805975 hasConcept C190283241 @default.
• W2113805975 hasConcept C2777025900 @default.
• W2113805975 hasConcept C2778227246 @default.
• W2113805975 hasConcept C2780394083 @default.
• W2113805975 hasConcept C502942594 @default.
• W2113805975 hasConcept C55493867 @default.
• W2113805975 hasConcept C71924100 @default.
• W2113805975 hasConceptScore W2113805975C128473837 @default.
• W2113805975 hasConceptScore W2113805975C142724271 @default.
• W2113805975 hasConceptScore W2113805975C167734588 @default.
• W2113805975 hasConceptScore W2113805975C185592680 @default.
• W2113805975 hasConceptScore W2113805975C190283241 @default.
• W2113805975 hasConceptScore W2113805975C2777025900 @default.
• W2113805975 hasConceptScore W2113805975C2778227246 @default.
• W2113805975 hasConceptScore W2113805975C2780394083 @default.
• W2113805975 hasConceptScore W2113805975C502942594 @default.

• next